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Non-Hodgkin lymphoma (NHL) is a heterogeneous group
of cancers that comprise !90% of lymphomas, the major-
ity (85%–90%) originating from B lymphocytes;[1] NHL
includes indolent forms (e.g. follicular lymphoma [FL]), as
well as aggressive forms (e.g. diffuse large B-cell lymph-
oma [DLBCL]). Although NHL is highly responsive to
standard front-line immunochemotherapy, which includes
the anti-CD20 antibody, rituximab, with cyclophospha-
mide, doxorubicin, vincristine, and prednisone (R-
CHOP),[2] many patients will relapse, develop refractory
disease, or develop rituximab resistance.[2,3] Despite clear
improvements in outcome in the post-rituximab era, prog-
nosis for patients in the relapsed/refractory setting
remains poor, with one study reporting a median overall
survival (OS) of only 0.7 months in DLBCL patients with
progressive disease following initial R-CHOP therapy.[2] In
addition, chemotherapy regimens are highly aggressive
and the associated side effects can reduce efficacy and
quality of life in some patients, making less toxic agents
desirable.
In many lymphoid malignancies, the immunomodula-
tory agent (IMiDVR ) lenalidomide exhibits versatile anti-
tumor properties that include immunomodulatory,
antiproliferative, and antiangiogenic effects.[4]
Lenalidomide, in combination or as single-agent therapy,
has demonstrated clinical activity in both treatment-naive
and relapsed/refractory NHL patient populations, including
DLBCL, FL, mantle cell lymphoma (MCL), marginal zone
lymphoma, small lymphocytic lymphoma, and T-cell
lymphoma (covered in detail by Witzig et al.).[5] Patients
with relapsed/refractory indolent and aggressive NHL
have achieved 23%–35% overall response rates (ORR) with
lenalidomide monotherapy.[6–8] A retrospective analysis
reported clinical benefit from single-agent lenalidomide in
relapsed/refractory DLBCL (ORR 28%), with preferential
activity in patients with non-germinal center B-cell (non-
GCB) versus GCB disease (ORR 53% versus 9%, respect-
ively, p¼ 0.006).[9] Lenalidomide plus rituximab (R2) has
demonstrated activity in multiple phase 2 studies across
various NHL subpopulations in the relapsed/refractory set-
ting. For example, R2 treatment resulted in 74% ORR (44%
complete response [CR]) and 12.4 months’ median pro-
gression-free survival (PFS) in patients with indolent
lymphoma,[10] and 33% ORR (22% CR) and 3.7 months’
and 10.7 months’ median PFS and OS, respectively, in
patients with aggressive lymphoma.[11] A recent study in
rituximab-resistant NHL and MCL patients showed that
addition of rituximab to lenalidomide monotherapy sig-
nificantly increased response (63% ORR) compared with
lenalidomide alone (30% ORR), with a more pronounced
response in the FL subpopulation (65% ORR and 19%
ORR, respectively).[12] Based on established efficacy in
multiple myeloma, lenalidomide in combination with the
anti-inflammatory agent dexamethasone (LenDex) was
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investigated in patients with heavily pretreated, relapsed/
refractory MCL (N¼ 33).[13] At final assessment, ORR was
52% (24% CR) and median PFS and OS were 12 and 20
months, respectively.[13]
We have previously reported results from a subset of
patients who received lenalidomide monotherapy in a
multicenter, retrospective, observational study that investi-
gated the efficacy and safety of off-label lenalidomide use
in patients with NHL.[14] Here, we present data from a
subset of patients with NHL who received R2 or LenDex.
Eligible patients included those with FL, DLBCL, MCL,
T-cell lymphoma or other types of NHL with histology not
specified (NHL-NOS) who received lenalidomide combin-
ation therapy through the Named Patient Program (NPP)
active in Italy from April 2008 to November 2010.[14] A
detailed description of the study methodology has been
described previously,[14] and all work from this study was
conducted in accordance with the International
Conference on Harmonisation and Declaration of Helsinki
guidelines (the REVEAL Study, AIFA id224). Combination
treatments and lenalidomide doses used reflect local clin-
ical practice guidelines and participating investigators’
preferences. All treatments were planned until progression
or toxicity. Key primary endpoints included ORR, duration
of response, PFS, OS, time to response, and abnormalities
in laboratory data and adverse events (AEs). Descriptive
statistics are presented as means, medians, standard devi-
ations, or ranges for continuous variables and as counts
or percentages for categorical variables. Time-to-event
variables (i.e. PFS and OS) were summarized with
Kaplan–Meier estimates at various time points along with
the standard errors, but were limited by the censoring of
the variable, and included time to event or last known
date without an event.
Out of 180 total patients, patients receiving lenalido-
mide monotherapy were the subject of an earlier publi-
cation;[14] this report focuses on the 92 patients with
NHL who were treated with either R2 (n¼ 24) or LenDex
(n¼ 68). The median number of treatment cycles was 4
in the R2 group and 3 in the LenDex group. The median
number of previous treatments was three. Almost half
(49%) of patients were refractory to rituximab therapy
(Table 1). The majority of the population was composed
of patients with DLBCL (52%) and MCL (26%). Median
duration of follow-up was 12.4 and 6.9 months for the
R2 and LenDex treatment groups, respectively. Overall
response rates (Table 2) in this heavily pretreated popu-
lation were similar between patients treated with R2
(42%) or LenDex (40%), and stable disease was observed
in 42% and 32% of patients, respectively. In patients
who responded to previous therapy, ORRs were higher
compared with those who were refractory to previous
therapies in both the R2 (50% and 33%) and LenDex
(50% and 30%) groups (Supplemental Table I). When
analyzed by NHL histological subtype, following R2 ther-
apy, the highest ORRs were observed in patients with FL
(75%), lymphocytic (67%), transformed lymphoma (40%),
and DLBCL (30%; data not shown). In patients treated
with LenDex, the highest ORRs were observed in patients
with DLBCL (50%), FL (40%), and MCL (28%; data not
shown). Duration of response appeared to vary among
different NHL histological subtypes (data not shown) and
lenalidomide dose levels (Supplemental Figure 1) in both
treatment groups. Median duration of response was 8.
1 ± 14.1 months and 3.7 ± 9.0 months in patients treated
with R2 and LenDex, respectively. Median PFS (95% CI)
was 8.0 months (2.3–12.7 months) in patients receiving
R2 and 5.3 months (2.8–10.9 months) in patients receiv-
ing LenDex (Supplemental Figure 2a). Median OS (95%
CI) was 8.0 months (3.9–15.8 months) in patients receiv-
ing R2 and 7.9 months (4.3–12.8 months) in patients
receiving LenDex (Supplemental Figure 2b). At 12
months, PFS and OS were 49% and 60%, respectively, in
patients treated with R2, and 43% and 52%, respectively,
in those treated with LenDex. PFS and OS remained con-
sistent at two and three years for both treatment groups
(Table 2).
Observed AEs in patients treated with R2 and LenDex
(Supplemental Table II) included neutropenia (n¼ 12 and
n¼ 15), leukopenia (n¼ 8 and n¼ 4), thrombocytopenia
Table 1. Demographics and patient characteristics at study entry.
Characteristic R2 (n¼ 24) LenDex (n¼ 68) Total (n¼ 92)
Median age, years (range) 63 (42–92) 72 (37–91) 69 (37–92)
Males, n (%) 19 (79.2) 38 (55.9) 57 (62.0)
Bulky disease (>7 cm), n (%) 6 (25.0) 21 (30.9) 27 (29.4)
Median time from diagnosis to first dose of lenalidomide, years (range) 2 (0.4–9.9) 3.2 (0.5–14.6) 3.1 (0.4–14.6)
Prior treatment regimens, median (range) 3.5 (1–9) 3 (0–14) 3 (0–14)
Refractory to rituximab,a n (%) 15 (62.5) 30 (44.1) 45 (48.9)
NHL histological subtype, n (%)b
Follicular lymphoma 4 (16.7) 5 (7.4) 9 (9.8)
Diffuse large B-cell lymphoma 10 (41.7) 38 (55.9) 48 (52.2)
Mantle cell lymphoma 6 (25.0) 18 (26.5) 24 (26.1)
Transformed lymphoma 0 (0.0) 5 (7.4) 5 (5.4)
Lymphocytic 3 (12.5) 1 (1.5) 4 (4.4)
Other 1 (4.2) 3 (4.4) 4 (4.4)
LenDex: lenalidomideþ dexamethasone; NHL: non-Hodgkin lymphoma; R2: lenalidomideþ rituximab.
aRefractory patients were defined per protocol as patients who had less than a partial response or had disease progression within six
months after completion of a prior therapy.
bPatients can be classified in more than one histological subtype.
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(n¼ 7 and n¼ 12), anemia (n¼ 6 and n¼ 11) and pyrexia
(n¼ 5 and n¼ 7), which are consistent with other pub-
lished reports of R2 or LenDex regimens in pretreated
NHL populations.[10,12,13] There were no reports of rash
in the R2 group versus 2 reports in the LenDex group.
Serious AEs included thrombocytopenia (n¼ 0 and n¼ 2)
and pyrexia (n¼ 1 and n¼ 1) in patients treated with R2
and LenDex, respectively.
This study suggests that R2 and LenDex are viable
treatment options for patients with relapsed/refractory
NHL in real-world clinical practice, a conclusion similar
to that reported from large-scale clinical trials. The
effectiveness and safety of lenalidomide-containing
therapies in relapsed/refractory NHL have been demon-
strated in numerous phase 2 trials.[10,12,13] Although
patient numbers were small in this retrospective study,
favorable response rates were observed with R2 (42%)
and LenDex (40%) therapies, and both regimens were
well-tolerated with safety profiles similar to that reported
in other clinical trials. Although the overall results
appear promising, there were limitations to this retro-
spective analysis. The small population size and variabil-
ity of NHL subtypes made it difficult to perform rigorous
statistical analysis. Therefore, the effect of R2 and
LenDex therapies on individual NHL subtypes could not
be evaluated in depth.
More recently, several phase 2 studies have suggested
that lenalidomide can function synergistically with rituxi-
mab to overcome rituximab-resistance in patients with
indolent NHL and MCL. In patients with rituximab-resistant
NHL and MCL (N¼ 50), the ORR increased from 30% in
those treated with lenalidomide monotherapy to 63%
after the addition of rituximab.[12] An additional trial in
patients with FL, MCL, marginal zone lymphoma, and
small lymphocytic lymphoma treated with LenDex
(N¼ 27) demonstrated an increase in ORR from 29% to
58% after the addition of lenalidomide.[15] In this study,
both the R2 and LenDex regimens demonstrated clinical
activity in this highly pretreated population, many of
whom (49%) were refractory to previous rituximab ther-
apy. Although patients who responded to previous treat-
ments achieved better responses in both groups (ORR
!50%), patients who relapsed still responded to both
lenalidomide-containing therapies (ORR !30%). Further
analysis is warranted to determine the efficacy of either
regimen in a rituximab-resistant population.
Potential conflict of interest: Disclosure forms provided
by the authors are available with the full text of this article at
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